J H Taylor
Princeton University
H-index: 148
North America-United States
Description
J H Taylor, With an exceptional h-index of 148 and a recent h-index of 109 (since 2020), a distinguished researcher at Princeton University, specializes in the field of Radio Astronomy, pulsars.
His recent articles reflect a diverse array of research interests and contributions to the field:
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the EMPA-KIDNEY trial
The optimal number of induction chemotherapy cycles in cN+ bladder cancer
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised …
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
Childhood‐onset lupus nephritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: Short‐term kidney status and variation in care
Search for light Higgs bosons from supersymmetric cascade decays in [... formula...] collisions at [... formula...]
Measurement of differential cross sections for the production of a Z boson in association with jets in proton-proton collisions at s= 13 TeV
Machine chuck jaws and method of manufacture
Professor Information
University | Princeton University |
|---|---|
Position | Professor of Physics |
Citations(all) | 109479 |
Citations(since 2020) | 61563 |
Cited By | 80925 |
hIndex(all) | 148 |
hIndex(since 2020) | 109 |
i10Index(all) | 632 |
i10Index(since 2020) | 456 |
University Profile Page | Princeton University |
Research & Interests List
Radio Astronomy
pulsars
Top articles of J H Taylor
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the EMPA-KIDNEY trial
BackgroundSodium–glucose co-transporter-2 (SGLT2) inhibitors reduce progression of chronic kidney disease and the risk of cardiovascular morbidity and mortality in a wide range of patients. However, their effects on kidney disease progression in some patients with chronic kidney disease are unclear because few clinical kidney outcomes occurred among such patients in the completed trials. In particular, some guidelines stratify their level of recommendation about who should be treated with SGLT2 inhibitors based on diabetes status and albuminuria. We aimed to assess the effects of empagliflozin on progression of chronic kidney disease both overall and among specific types of participants in the EMPA-KIDNEY trial.MethodsEMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA), and …
Authors
N Staplin,R Haynes,PK Judge,C Wanner,JB Green,J Emberson,D Preiss,KJ Mayne,SYA Ng,E Sammons,D Zhu,M Hill,W Stevens,K Wallendszus,S Brenner,AK Cheung,ZH Liu,J Li,LS Hooi,WJ Liu,T Kadowaki,M Nangaku,A Levin,D Cherney,AP Maggioni,R Pontremoli,R Deo,S Goto,X Rossello,KR Tuttle,D Steubl,M Petrini,S Seidi,MJ Landray,C Baigent,WG Herrington,S Abat,R Abd Rahman,R Abdul Cader,MI Abdul Hafidz,MZ Abdul Wahab,NK Abdullah,T Abdul-Samad,M Abe,N Abraham,S Acheampong,P Achiri,JA Acosta,A Adeleke,V Adell,R Adewuyi-Dalton,N Adnan,A Africano,M Agharazii,F Aguilar,A Aguilera,M Ahmad,MK Ahmad,NA Ahmad,NH Ahmad,NI Ahmad,N Ahmad Miswan,H Ahmad Rosdi,I Ahmed,S Ahmed,J Aiello,A Aitken,R AitSadi,S Aker,S Akimoto,A Akinfolarin,S Akram,F Alberici,C Albert,L Aldrich,M Alegata,L Alexander,S Alfaress,M Alhadj Ali,A Ali,R Alicic,A Aliu,R Almaraz,R Almasarwah,J Almeida,A Aloisi,L Al-Rabadi,D Alscher,P Alvarez,B Al-Zeer,M Amat,C Ambrose,H Ammar,Y An,L Andriaccio,K Ansu,A Apostolidi,N Arai,H Araki,S Araki,A Arbi,O Arechiga,S Armstrong,T Arnold,S Aronoff,W Arriaga,J Arroyo,D Arteaga,S Asahara,A Asai,N Asai,S Asano,M Asawa,MF Asmee,F Aucella,M Augustin,A Avery,A Awad,IY Awang,M Awazawa,A Axler,W Ayub,Z Azhari,R Baccaro,C Badin,B Bagwell,E Bahlmann-Kroll,AZ Bahtar,D Bains,H Bajaj,R Baker,E Baldini,B Banas,D Banerjee,S Banno,S Bansal,S Barberi,S Barnes,C Barnini,C Barot,K Barrett,R Barrios,B Bartolomei Mecatti,I Barton,J Barton,W Basily,S Bavanandan,A Baxter,L Becker,S Beddhu
Journal
The Lancet Diabetes & Endocrinology
Published Date
2024/1/1
The optimal number of induction chemotherapy cycles in cN+ bladder cancer
Objective To investigate the optimal number of induction chemotherapy cycles needed to achieve a pathological response in patients with clinically lymph node‐positive (cN+) bladder cancer (BCa) who received three or four cycles of induction chemotherapy followed by consolidative radical cystectomy (RC) with pelvic lymph node dissection. Patients and Methods We included 388 patients who received three or four cycles of cisplatin/gemcitabine or (dose‐dense) methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), followed by consolidative RC for cTanyN1–3M0 BCa. We compared pathological complete (pCR = ypT0N0) and objective response (pOR = yp ≤T1N0) between treatment groups. Predictors of pCR and/or pOR were assessed using uni‐ and multivariable logistic regression analysis. The secondary endpoints were overall (OS) and cancer‐specific survival (CSS). We evaluated the …
Authors
Markus von Deimling,Laura S Mertens,Marc Furrer,Roger Li,Guus AH Tendijck,Jacob Taylor,Felice Crocetto,Moritz Maas,Andrea Mari,Renate Pichler,Marco Moschini,Karl H Tully,David D'Andrea,Ekaterina Laukhtina,Francesco Del Giudice,Gautier Marcq,Maud Velev,Andrea Gallioli,Simone Albisinni,Keiichiro Mori,Abhinav Khanna,Michael Rink,Margit Fisch,Andrea Minervini,Peter C Black,Yair Lotan,Philippe E Spiess,Bernhard Kiss,Shahrokh F Shariat,Benjamin Pradere,CLIPOLY Study Group Collaborators,Luca Afferi,Alessandro Antonelli,Luca Antonelli,Mara Bacchiani,Alberto Bianchi,Ronan Flippot,Mattia Longoni,Elisabeth Maier,Nicolas Penel,Julien Sarkis,Francesco Soria,Solomon Woldu
Journal
BJU international
Published Date
2024/3/12
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised …
BackgroundPaediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS), also known as multisystem inflammatory syndrome in children (MIS-C) emerged in April, 2020. The paediatric comparisons within the RECOVERY trial aimed to assess the effect of intravenous immunoglobulin or corticosteroids compared with usual care on duration of hospital stay for children with PIMS-TS and to compare tocilizumab (anti-IL-6 receptor monoclonal antibody) or anakinra (anti-IL-1 receptor antagonist) with usual care for those with inflammation refractory to initial treatment.MethodsWe did this randomised, controlled, open-label, platform trial in 51 hospitals in the UK. Eligible patients were younger than 18 years and had been admitted to hospital for PIMS-TS. In the first randomisation, patients were randomly assigned (1: 1: 1) to usual care (no additional treatments), usual care plus …
Authors
Saul N Faust,Richard Haynes,Christine E Jones,Natalie Staplin,Elizabeth Whittaker,Thomas Jaki,Ed Juszczak,Enti Spata,Mandy Wan,Alasdair Bamford,Paul Dimitri,Adam Finn,John Furness,Athimalaipet V Ramanan,Christopher Gale,Katrina Cathie,Simon Drysdale,Jolanta Bernatoniene,Clare Murray,Charles C Roehr,Paul Fleming,Andrew Riordan,Srini Bandi,Deepthi Jyothish,Jennifer Evans,Marieke Emonts,Dominic Kelly,Nazima Pathan,Patrick Davies,Rosie Hague,Louisa Pollock,Malcolm G Semple,Leon Peto,J Kenneth Baillie,Maya Buch,Katie Jeffery,Marian Knight,Wei Shen Lim,Alan Montgomery,Aparna Mukherjee,Andrew Mumford,Kathryn Rowan,Guy Thwaites,Marion Mafham,Jonathan Emberson,Martin J Landray,Peter W Horby,Lucy Chappell,Jeremy Day,DV Dung,NN Quang,E Burhan,B Alisjahbana,J Koirala,S Basnet,E Kestelyn,B Basnyat,P Gyanwali,RL Hamers,P Sandercock,J Darbyshire,D DeMets,R Fowler,D Lalloo,M Munavvar,I Roberts,A Warris,J Wittes,A Craddock-Bamford,J Barton,A Basoglu,R Brown,W Brudlo,E Denis,L Fletcher,S Howard,S Musini,K Taylor,G Cui,B Goodenough,A King,M Lay,D Murray,W Stevens,K Wallendszus,R Welsh,C Crichton,J Davies,R Goldacre,C Harper,F Knight,M Nunn,H Salih,J Welch,M Campbell,G Pessoa-Amorim,M Zayed,J Wiles,G Bagley,S Cameron,S Chamberlain,B Farrell,H Freeman,A Kennedy,A Whitehouse,S Wilkinson,C Wood,C Reith,K Davies,H Halls,L Holland,R Truell,K Wilson,Emma Lingwood,L Howie,M Lunn,Penelope Rodgers,J Amuasi,K Baird,T Bao,M Bittaye,J Bonney,U D'Alessandro,M Dhimal,T Huyen,A Jagne,A Karkey,O Maiga,E Matey,B Nadjm,J Nel,S Pant,K Puspatriani,M Rahardjani,S Raijal,H Rees,A Rimainar,C Roberts,A Rocca,S Shrestha,E Usuf,C Vidaillic,F Wulandari,A Alexander,M Amezaga,C Armah,A Asghar,P Aubrey,K Barker-Williams,A Barnard
Journal
The Lancet Child & Adolescent Health
Published Date
2024/3/1
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
BackgroundThe EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population.MethodsEMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease …
Authors
Parminder K Judge,Natalie Staplin,Kaitlin J Mayne,Christoph Wanner,Jennifer B Green,Sibylle J Hauske,Jonathan R Emberson,David Preiss,Sarah YA Ng,Alistair J Roddick,Emily Sammons,Doreen Zhu,Michael Hill,Will Stevens,Karl Wallendszus,Susanne Brenner,AK Cheung,ZH Liu,J Li,LS Hooi,WJ Liu,T Kadowaki,M Nangaku,A Levin,D Cherney,AP Maggioni,R Pontremoli,R Deo,S Goto,X Rossello,KR Tuttle,D Steubl,D Massey,MJ Landray,C Baigent,R Haynes,WG Herrington,S Abat,R Abd Rahman,R Abdul Cader,MI Abdul Hafidz,MZ Abdul Wahab,NK Abdullah,T Abdul-Samad,M Abe,N Abraham,S Acheampong,P Achiri,JA Acosta,A Adeleke,V Adell,R Adewuyi-Dalton,N Adnan,A Africano,M Agharazii,F Aguilar,A Aguilera,M Ahmad,MK Ahmad,NA Ahmad,NH Ahmad,NI Ahmad,N Ahmad Miswan,H Ahmad Rosdi,I Ahmed,S Ahmed,J Aiello,A Aitken,R AitSadi,S Aker,S Akimoto,A Akinfolarin,S Akram,F Alberici,C Albert,L Aldrich,M Alegata,L Alexander,S Alfaress,M Alhadj Ali,A Ali,R Alicic,A Aliu,R Almaraz,R Almasarwah,J Almeida,A Aloisi,L Al-Rabadi,D Alscher,P Alvarez,B Al-Zeer,M Amat,C Ambrose,H Ammar,Y An,L Andriaccio,K Ansu,A Apostolidi,N Arai,H Araki,S Araki,A Arbi,O Arechiga,S Armstrong,T Arnold,S Aronoff,W Arriaga,J Arroyo,D Arteaga,S Asahara,A Asai,N Asai,S Asano,M Asawa,MF Asmee,F Aucella,M Augustin,A Avery,A Awad,IY Awang,M Awazawa,A Axler,W Ayub,Z Azhari,R Baccaro,C Badin,B Bagwell,E Bahlmann-Kroll,AZ Bahtar,D Bains,H Bajaj,R Baker,E Baldini,B Banas,D Banerjee,S Banno,S Bansal,S Barberi,S Barnes,C Barnini,C Barot,K Barrett,R Barrios,B Bartolomei Mecatti,I Barton,J Barton,W Basily,S Bavanandan,A Baxter,L Becker
Journal
The Lancet Diabetes & Endocrinology
Published Date
2024/1/1
Childhood‐onset lupus nephritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: Short‐term kidney status and variation in care
Objective The goal was to characterize short‐term kidney status and describe variation in early care utilization in a multicenter cohort of patients with childhood‐onset systemic lupus erythematosus (cSLE) and nephritis. Methods We analyzed previously collected prospective data from North American patients with cSLE with kidney biopsy‐proven nephritis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry from March 2017 through December 2019. We determined the proportion of patients with abnormal kidney status at the most recent registry visit and applied generalized linear mixed models to identify associated factors. We also calculated frequency of medication use, both during induction and ever recorded. Results We identified 222 patients with kidney biopsy–proven nephritis, with 64% class III/IV nephritis on initial biopsy. At the most recent registry visit at median …
Authors
Emily A Smitherman,Rouba A Chahine,Timothy Beukelman,Laura B Lewandowski,AKM Fazlur Rahman,Scott E Wenderfer,Jeffrey R Curtis,Aimee O Hersh,CARRA Registry Investigators,N Abel,K Abulaban,A Adams,M Adams,R Agbayani,J Aiello,S Akoghlanian,C Alejandro,E Allenspach,R Alperin,M Alpizar,G Amarilyo,W Ambler,E Anderson,S Ardoin,S Armendariz,E Baker,I Balboni,S Balevic,L Ballenger,S Ballinger,N Balmuri,F Barbar‐Smiley,L Barillas‐Arias,M Basiaga,K Baszis,M Becker,H Bell‐Brunson,E Beltz,H Benham,S Benseler,W Bernal,T Beukelman,T Bigley,B Binstadt,C Black,M Blakley,J Bohnsack,J Boland,A Boneparth,S Bowman,C Bracaglia,E Brooks,M Brothers,A Brown,H Brunner,M Buckley,M Buckley,H Bukulmez,D Bullock,B Cameron,S Canna,L Cannon,P Carper,V Cartwright,E Cassidy,L Cerracchio,E Chalom,J Chang,A Chang‐Hoftman,V Chauhan,P Chira,T Chinn,K Chundru,H Clairman,D Co,A Confair,H Conlon,R Connor,A Cooper,J Cooper,S Cooper,C Correll,R Corvalan,D Costanzo,R Cron,L Curiel‐Duran,T Curington,M Curry,A Dalrymple,A Davis,C Davis,C Davis,T Davis,F De Benedetti,D De Ranieri,J Dean,F Dedeoglu,M DeGuzman,N Delnay,V Dempsey,E DeSantis,T Dickson,J Dingle,B Donaldson,E Dorsey,S Dover,J Dowling,J Drew,K Driest,Q Du,K Duarte,D Durkee,E Duverger,J Dvergsten,A Eberhard,M Eckert,K Ede,B Edelheit,C Edens,C Edens,Y Edgerly,M Elder,B Ervin,S Fadrhonc,C Failing,D Fair,M Falcon,L Favier,S Federici,B Feldman,J Fennell,I Ferguson,P Ferguson,B Ferreira,R Ferrucho,K Fields,T Finkel,M Fitzgerald,C Fleming,O Flynn,L Fogel,E Fox,M Fox,L Franco,M Freeman,K Fritz,S Froese,R Fuhlbrigge,J Fuller,N George
Journal
Arthritis Care & Research
Published Date
2023/7
Search for light Higgs bosons from supersymmetric cascade decays in [... formula...] collisions at [... formula...]
A search is reported for pairs of light Higgs bosons (H 1) produced in supersymmetric cascade decays in final states with small missing transverse momentum. A data set of LHC pp collisions collected with the CMS detector at s= 13 TeV and corresponding to an integrated luminosity of 138 fb-1 is used. The search targets events where both H 1 bosons decay into pairs that are reconstructed as large-radius jets using substructure techniques. No evidence is found for an excess of events beyond the background expectations of the standard model (SM). Results from the search are interpreted in the next-to-minimal supersymmetric extension of the SM, where a “singlino” of small mass leads to squark and gluino cascade decays that can predominantly end in a highly Lorentz-boosted singlet-like H 1 and a singlino-like neutralino of small transverse momentum. Upper limits are set on the product of the squark or gluino …
Authors
Armen Tumasyan,Waldemar Adam,Janik Walter Andrejkovic,Thomas Bergauer,Suman Chatterjee,Konstantinos Damanakis,Marko Dragicevic,A Escalante Del Valle,Rudolf Fruehwirth,Manfred Jeitler,N Krammer,L Lechner,D Liko,I Mikulec,P Paulitsch,FM Pitters,J Schieck,R Schöfbeck,D Schwarz,S Templ,W Waltenberger,C-E Wulz,MR Darwish,EA De Wolf,Tahys Janssen,T Kello,A Lelek,H Rejeb Sfar,P Van Mechelen,S Van Putte,N Van Remortel,ES Bols,J D’Hondt,A De Moor,M Delcourt,H El Faham,S Lowette,S Moortgat,A Morton,D Müller,AR Sahasransu,S Tavernier,W Van Doninck,D Vannerom,D Beghin,B Bilin,B Clerbaux,G De Lentdecker,L Favart,AK Kalsi,K Lee,M Mahdavikhorrami,I Makarenko,L Moureaux,S Paredes,L Pétré,A Popov,N Postiau,E Starling,L Thomas,M Vanden Bemden,C Vander Velde,P Vanlaer,T Cornelis,D Dobur,J Knolle,L Lambrecht,G Mestdach,M Niedziela,C Rendón,C Roskas,A Samalan,K Skovpen,M Tytgat,B Vermassen,L Wezenbeek,A Benecke,A Bethani,G Bruno,F Bury,C Caputo,P David,C Delaere,IS Donertas,A Giammanco,K Jaffel,Sa Jain,V Lemaitre,K Mondal,J Prisciandaro,A Taliercio,M Teklishyn,TT Tran,P Vischia,S Wertz,GA Alves,C Hensel,A Moraes,P Rebello Teles,WL Aldá Júnior,M Alves Gallo Pereira,M Barroso Ferreira Filho,H Brandao Malbouisson,W Carvalho,J Chinellato,EM Da Costa,GG Da Silveira,D De Jesus Damiao,V Dos Santos Sousa,S Fonseca De Souza,C Mora Herrera,K Mota Amarilo,L Mundim,H Nogima,A Santoro,SM Silva Do Amaral,A Sznajder,M Thiel,F Torres Da Silva De Araujo,A Vilela Pereira,CA Bernardes,L Calligaris,TR Fernandez Perez Tomei,EM Gregores,DS Lemos,PG Mercadante,SF Novaes,Sandra S Padula,A Aleksandrov,G Antchev,R Hadjiiska,P Iaydjiev,M Misheva,M Rodozov,M Shopova,G Sultanov,A Dimitrov,T Ivanov,L Litov,B Pavlov,P Petkov,A Petrov,T Cheng,T Javaid,M Mittal,L Yuan,M Ahmad,G Bauer,C Dozen,Z Hu
Journal
The European Physical Journal C
Published Date
2023/7/6
Measurement of differential cross sections for the production of a Z boson in association with jets in proton-proton collisions at s= 13 TeV
A measurement is presented of the production of Z bosons that decay into two electrons or muons in association with jets, in proton-proton collisions at a center-of-mass energy of 13 TeV. The data were recorded by the CMS Collaboration at the LHC with an integrated luminosity of 35.9 fb− 1. The differential cross sections are measured as a function of the transverse momentum (p T) of the Z boson and the transverse momentum and rapidities of the five jets with largest p T. The jet multiplicity distribution is measured for up to eight jets. The hadronic activity in the events is estimated using the scalar sum of the p T of all the jets. All measurements are unfolded to the stable-particle level and compared with predictions from various Monte Carlo event generators, as well as with expectations at leading and next-to-leading orders in perturbative quantum chromodynamics.
Authors
Armen Tumasyan,Wolfgang Adam,Janik Walter Andrejkovic,Thomas Bergauer,Suman Chatterjee,Marko Dragicevic,Alberto Escalante Del Valle,Rudolf Fruehwirth,Manfred Jeitler,Natascha Krammer,Lukas Lechner,Dietrich Liko,Ivan Mikulec,Florian Michael Pitters,Jochen Schieck,Robert Schöfbeck,Markus Spanring,Sebastian Templ,Wolfgang Waltenberger,Claudia-Elisabeth Wulz,Mohamed Rashad Darwish,Eddi A De Wolf,Tahys Janssen,Tomas Kello,Aleksandra Lelek,H Rejeb Sfar,Pierre Van Mechelen,Senne Van Putte,F Blekman,ES Bols,J D’Hondt,J De Clercq,M Delcourt,S Lowette,S Moortgat,A Morton,D Müller,AR Sahasransu,S Tavernier,W Van Doninck,P Van Mulders,D Beghin,B Bilin,B Clerbaux,G De Lentdecker,L Favart,A Grebenyuk,AK Kalsi,K Lee,M Mahdavikhorrami,I Makarenko,L Moureaux,L Pétré,A Popov,N Postiau,E Starling,L Thomas,M Vanden Bemden,C Vander Velde,Pascal Vanlaer,David Vannerom,Liam Wezenbeek,Tom Cornelis,Didar Dobur,Marek Gruchala,Gianny Mestdach,Marek Niedziela,Christos Roskas,Kirill Skovpen,Michael Tytgat,Willem Verbeke,Basile Vermassen,Martina Vit,Agni Bethani,Giacomo Bruno,F Bury,Claudio Caputo,Pieter David,Christophe Delaere,Izzeddin Suat Donertas,Andrea Giammanco,Vincent Lemaitre,Kuntal Mondal,Jessica Prisciandaro,Angela Taliercio,Maksym Teklishyn,Pietro Vischia,Sébastien Wertz,Sophie Wuyckens,GA Alves,Carsten Hensel,Arthur Moraes,WL Aldá Júnior,Barroso Ferreira Filho,H Brandao Malbouisson,Wagner Carvalho,Jose Chinellato,Eliza Melo Da Costa,Gustavo Gil Da Silveira,Dilson de Jesus Damiao,S Fonseca De Souza,D Matos Figueiredo,C Mora Herrera,Kevin Mota Amarilo,Luiz Mundim,Helio Nogima,P Rebello Teles,LJ Sanchez Rosas,Alberto Santoro,SM Silva Do Amaral,Andre Sznajder,Mauricio Thiel,F Torres Da Silva De Araujo,A Vilela Pereira,Cesar Augusto Bernardes,Luigi Calligaris,TR Tomei,EM Gregores,DS Lemos,Pedro G Mercadante,Sergio F Novaes,Sandra S Padula,Aleksandar Aleksandrov,Georgy Antchev,I Atanassov,Roumyana Hadjiiska,Plamen Iaydjiev,Milena Misheva,Mircho Rodozov,Mariana Shopova,Georgi Sultanov,Anton Dimitrov,Todor Ivanov,Leander Litov,Borislav Pavlov,Peicho Petkov,Anton Petrov,Tongguang Cheng,Wenxing Fang,Qianying Guo,Tahir Javaid,Monika Mittal,Hanwen Wang,Li Yuan,Muhammad Ahmad,Gerry Bauer,Candan Dozen,Zhen Hu,Jordan Martins,Yi Wang
Journal
Physical Review D
Published Date
2023/9/6
Machine chuck jaws and method of manufacture
Machine chuck jaws, and a related method of manufacture, are provided. The machine chuck jaws are formed from an additive manufacturing process and include one or more gripping pads per chuck jaw. An axial stop is also formed from an additive manufacturing process and provides a flat surface for workpiece placement. The gripping pads equally distribute the clamping pressure, and the additive manufacturing process provides unique shaping capabilities and a honeycomb internal cross-section, thereby achieving a lightweight design. The reduction in weight allows for a decrease in pneumatic pressure used to actuate the jaws, resulting in a corresponding reduction in the clamping pressure which helps improve the form of the workpiece being machined.
Published Date
2023/4/20
Professor FAQs
What is J H Taylor's h-index at Princeton University?
The h-index of J H Taylor has been 109 since 2020 and 148 in total.
What are J H Taylor's top articles?
The articles with the titles of
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the EMPA-KIDNEY trial
The optimal number of induction chemotherapy cycles in cN+ bladder cancer
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised …
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
Childhood‐onset lupus nephritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: Short‐term kidney status and variation in care
Search for light Higgs bosons from supersymmetric cascade decays in [... formula...] collisions at [... formula...]
Measurement of differential cross sections for the production of a Z boson in association with jets in proton-proton collisions at s= 13 TeV
Machine chuck jaws and method of manufacture
...
are the top articles of J H Taylor at Princeton University.
What are J H Taylor's research interests?
The research interests of J H Taylor are: Radio Astronomy, pulsars
What is J H Taylor's total number of citations?
J H Taylor has 109,479 citations in total.
Useful Links